Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors

Trial Identifier: D798MC00002
Sponsor: AstraZeneca
Start Date: August 2024
Primary Completion Date: November 2028
Study Completion Date: November 2028
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BR Ijuí, BR, 98700-000
BR Londrina, BR, 86015-520
BR São Caetano do Sul, BR, 09541-270
BR Vitoria, BR, 29043-260
CN Beijing, CN, CN-100730
CN Beijing, CN, 100730
CN Beijing, CN, 100142
CN Bengbu, CN, 233004
CN Changsha, CN, 410008
CN Changsha, CN, 410013
CN Changsha, CN, 410003
CN Chengdu, CN, 610072
CN Chengdu, CN, 610041
CN Chongqing, CN, 400030
CN Dongguan, CN, 523009
CN fuzhou, CN, 350011
CN Fuzhou, CN, 350014
CN Hangzhou, CN, 310022
CN Jining, CN, 272029
CN Kunming, CN, 650118
CN Nanchang, CN, 330006
CN Nanning, CN, 530021
CN Shandong, CN
CN Shandong, CN, 250117
CN Shanghai, CN, 200120
CN Shenyang, CN, 110004
CN Tianjin, CN, 300060
CN Wuhan, CN, 430022
CN Wuhan, CN, 430079
CN Wuhan, CN, 430040
CN Wuhan, CN, 430048
CN Wuhou District, CN, 610041
KR Namdong-gu, KR, 21565
KR Seoul, KR, 03722
TW Taichung, TW
TW Taipei, TW, 112
US, CA Los Angeles, CA, US, 90025
US, MD Baltimore, MD, US, 21201
US, NY Stony Brook, NY, US, 11794
US, OH Columbus, OH, US, 43210
VN Hanoi, VN, 100000
VN Ho Chi Minh City, VN, 700000